title: Effect of HAART on incident cancer and noncancer AIDS events among male HIV seroconverters.
abstract: OBJECTIVE
  To explore the impact of highly active antiretroviral therapy (HAART) on the prevention of AIDS-defining cancers relative to other AIDS-defining events.
  
  
  METHODS
  Prospective cohort study using 2,121 HIV+ male seroconverters (median age: 28 years, 51% white/non-Hispanic) in the Tri-Service AIDS Clinical Consortium (n = 1694) and the Multicenter AIDS Cohort Study (n = 427).
  
  
  METHODS
  Poisson regression models, with calendar periods to represent antiretroviral therapy, were extended to analyze first incident AIDS-defining cancers and other first AIDS-defining events as competing risks.
  
  
  RESULTS
  Eighty-one AIDS-defining cancers (64 Kaposi sarcomas; 17 non-Hodgkin lymphomas) and 343 other AIDS events occurred during 14,483 person-years in 1990-2006. The rate ratio of AIDS-defining cancers during the HAART calendar period was 0.26 (95% confidence limits: 0.15, 0.46) and of other AIDS-defining events was 0.28 (95% confidence limits: 0.21, 0.36) compared with the monotherapy/combination therapy calendar period, adjusting for age, infection duration, race, and cohort. The association of HAART with decreased AIDS incidence seemed to be equal (interaction ratio = 0.95 (95% confidence limits: 0.51, 1.74) for AIDS-defining cancers and other AIDS-defining events.
  
  
  CONCLUSIONS
  In human immunodeficiency virus-infected men, HAART seems equally protective against first AIDS-defining cancers and other first AIDS-defining events.
authors.affiliation: Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, 615 North Wolfe Street, Room E7133, Baltimore, MD 21205, USA. mshiels@jhsph.edu
authors.forename: Meredith S
authors.initials: MS
authors.lastname: Shiels
authors.forename: Stephen R
authors.initials: SR
authors.lastname: Cole
authors.forename: Scott
authors.initials: S
authors.lastname: Wegner
authors.forename: Haroutune
authors.initials: H
authors.lastname: Armenian
authors.forename: Joan S
authors.initials: JS
authors.lastname: Chmiel
authors.forename: Anuradha
authors.initials: A
authors.lastname: Ganesan
authors.forename: Vincent C
authors.initials: VC
authors.lastname: Marconi
authors.forename: Otoniel
authors.initials: O
authors.lastname: Martinez-Maza
authors.forename: Jeremy
authors.initials: J
authors.lastname: Martinson
authors.forename: Amy
authors.initials: A
authors.lastname: Weintrob
authors.forename: Lisa P
authors.initials: LP
authors.lastname: Jacobson
authors.forename: Nancy F
authors.initials: NF
authors.lastname: Crum-Cianflone
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000150:complications / Q000453:epidemiology*; D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000188:drug therapy*; D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D015497:HIV-1; D006801:Humans; D015994:Incidence; D008228:Lymphoma, Non-Hodgkin / Q000150:complications / Q000453:epidemiology*; D008297:Male; D011446:Prospective Studies; D012514:Sarcoma, Kaposi / Q000150:complications / Q000453:epidemiology*; D014481:United States
chemical_list: D019380:Anti-HIV Agents